Calidi Biotherapeutics' Engineered Virus Platform Targets Cancer

Calidi Biotherapeutics' platform utilizes engineered viruses to deliver genetic medicines directly to cancer cells. This approach aims to overcome the limitations of traditional cancer therapies by precisely targeting tumors and activating the immune system. The company's lead candidate, CLD-401, is designed for systemic delivery, allowing it to reach tumors throughout the body.

Calidi's RedTail platform is a key component of this technology, using an engineered oncolytic vaccinia virus encased in a protective envelope. This virus is designed to evade the immune system, circulate effectively, and deliver a potent genetic medicine (IL-15 superagonist) to destroy cancer cells and stimulate an immune response.

Preclinical data presented at AACR and ASCO demonstrated the platform's ability to target metastatic sites, bypass immune defenses, and activate CD8+ T cells and natural killer (NK) cells within the tumor microenvironment. These findings suggest that Calidi's approach can convert immunologically 'cold' tumors into 'hot' targets, potentially improving outcomes in difficult-to-treat cancers.

They are developing a precision genetic medicine platform for cancer treatment using engineered viruses.

It delivers genetic medicines directly to primary tumors and metastatic sites, aiming to destroy cancer cells and stimulate an immune response.

It's a key component of Calidi's technology, using an engineered oncolytic vaccinia virus to target tumors throughout the body.

Do you think this approach will revolutionize cancer treatment? Share this article with others who need to stay ahead of this trend!